Individualized neuro-regenerative care in Istanbul
Stem cell therapy for multiple sclerosis in Istanbul
Led by Uzm. Dr. Cihan Bolat, our medical team evaluates your MS history, neurological reports, and brain and spinal MRI scans to design a personalized Wharton's jelly MSC and exosome protocol aimed at modulating neuroinflammation and supporting neural repair signaling.
Understanding multiple sclerosis and our regenerative approach
Multiple sclerosis (MS) is an immune-mediated neurological condition in which misdirected immune cells cross the blood-brain barrier and target the protective myelin sheaths and oligodendrocytes of the brain and spinal cord. As myelin insulation becomes inflamed and stripped away, electrical signaling along nerve fibers slows or misfires, placing surviving axons under intense metabolic stress. For patients, this biological strain often translates into persistent neurological fatigue, limb weakness, balance and walking difficulties, sensory numbness or tingling, and reduced day-to-day stamina.
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) and WJ-MSC-derived exosomes are investigated for their ability to address both the immune and neural sides of this process. Inside the body, WJ-MSCs act as living biological regulators that calm overactive T-cell and B-cell responses, expand protective regulatory T cells (Tregs), and shift central microglia from destructive pro-inflammatory (M1) states toward reparative, tissue-supportive (M2) phenotypes. Simultaneously, WJ-MSCs and their nanoscale exosomes release a rich cargo of neurotrophic growth factors — including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF) — alongside regenerative microRNAs that nourish oligodendrocyte precursor cells, protect exposed axons from oxidative injury, and help restore a healthier environment for endogenous myelin repair.
At our clinic in Istanbul, led by Uzm. Dr. Cihan Bolat, every journey begins with a comprehensive evaluation of your neurological history, symptom profile, and recent brain and spinal MRI scans. Where clinically appropriate, our medical team designs an individualized multi-route protocol combining intrathecal WJ-MSC delivery into the cerebrospinal fluid, systemic intravenous WJ-MSC and exosome infusions, and intranasal exosome application. By pairing targeted peripheral immune modulation with direct central neurotrophic support alongside your ongoing neurologist care, our protocols aim to support steadier motor function, improved energy, clearer nerve conduction, and greater daily independence.
Reviewed by: Uzm. Dr. Cihan Bolat · Reviewed · Re-review due
What happens inside the body
What happens inside the body in multiple sclerosis — and how biologics help
Multiple sclerosis involves four interconnected biological processes within the immune system and central nervous system. Understanding each pathway shows how Wharton's jelly MSCs and exosomes interact with damaged tissues to support protection and repair.
Therapeutic objectives of our protocol
Our regenerative protocols are designed as supportive biological care in Istanbul while you continue your prescribed disease-modifying therapies and specialist neurological follow-up with your home physician.
Modulating autoreactive T-cell and B-cell inflammatory signaling across peripheral and central compartments
Calming chronic microglial activation and pro-inflammatory cytokine cascades within the central nervous system
Supporting neurotrophic factor signaling and the protective microenvironment around oligodendrocytes and demyelinated axons
Promoting neurovascular barrier integrity and intercellular repair communication via MSC-derived exosomes
Supporting daily energy, motor endurance, and neurological stability alongside your ongoing specialist care
01
Autoimmune demyelination & T/B-cell attack on myelin sheaths
In MS, autoreactive T cells and B cells mistakenly recognize myelin proteins as foreign targets, launching inflammatory attacks that strip the insulating myelin sheath from nerve fibers and disrupt signal conduction.
Intravenous and intrathecal Wharton's jelly MSCs help counter this process by releasing immunomodulatory molecules (such as PGE2, IDO, IL-10, and TGF-beta) that suppress aggressive T-cell proliferation and promote regulatory T-cell (Treg) balance. By calming this misdirected immune response, the biologics help shield remaining myelin sheaths and oligodendrocytes from ongoing autoimmune damage.
02
Microglial activation & chronic central neuroinflammation
Even between clinical relapses, resident microglia and astrocytes inside the brain and spinal cord can remain locked in a destructive M1 pro-inflammatory state, releasing free radicals and inflammatory cytokines that block natural tissue repair.
When delivered into the cerebrospinal fluid and supported by nanoscale exosomes, WJ-MSCs interact directly with central glial networks to guide microglia toward a reparative M2 phenotype. This shift reduces neurotoxic inflammation around plaques and creates a calmer biochemical environment where oligodendrocyte precursor cells can support myelin maintenance.
Chronic systemic inflammation weakens the tight junctions between endothelial cells lining cerebral blood vessels, making the blood-brain barrier leaky and allowing circulating immune cells and inflammatory mediators to infiltrate neural tissue.
Wharton's jelly MSCs and their vascular-supportive exosomes release angiopoietins, VEGF, and endothelial-stabilizing microRNAs that help repair microvascular lining integrity. Strengthening the neurovascular barrier reduces further immune infiltration while improving healthy microcirculation and oxygen delivery to recovering neural tracts.
04
Axonal metabolic stress & impaired trophic support
When nerve fibers lose their myelin insulation and the metabolic support normally provided by oligodendrocytes, exposed axons must expend far more energy to conduct signals, leading to mitochondrial exhaustion, conduction block, and severe clinical fatigue.
WJ-MSCs and exosomes supply concentrated neurotrophic factors — including BDNF, GDNF, NGF, and IGF-1 — alongside antioxidant enzymes that support mitochondrial bioenergetics inside stressed neurons. By nourishing demyelinated axons and supporting synaptic resilience, these signals help preserve nerve fiber integrity and functional signal transmission.
Why regenerative medicine is investigated
Scientific rationale for Wharton's jelly MSCs and exosomes
Biological rationale
Addressing both peripheral immune activation and central neuroinflammation
In multiple sclerosis, tissue injury is driven by two interconnected forces: autoreactive T and B lymphocytes entering from the peripheral bloodstream, and resident microglia and astrocytes sustaining chronic, smoldering inflammation inside the brain and spinal cord. When this inflammatory microenvironment persists, endogenous oligodendrocyte precursor cells struggle to mature and repair damaged myelin sheaths. Regenerative medicine focuses on quieting both peripheral immune triggers and central glial inflammation while restoring the local trophic signals required for axonal protection and remyelination support. By transforming a hostile lesion microenvironment into a more supportive biological niche, surviving neural pathways are given better conditions to stabilize and function.
WJ-MSCs & exosomes
Synergistic paracrine immunomodulation and vesicular repair signaling
Wharton's jelly-derived MSCs and their purified exosomes work in biological synergy to support repair across the central nervous system. Live WJ-MSCs sense inflammatory signals and respond dynamically by secreting anti-inflammatory cytokines (such as IL-10 and TGF-beta) and trophic factors (BDNF, GDNF, HGF, and IGF-1) that calm autoreactive lymphocytes and shield vulnerable neurons. Meanwhile, nanoscale WJ-MSC exosomes cross biological barriers and deliver concentrated regulatory microRNAs and signaling proteins directly into recipient glial cells, endothelial cells, and oligodendrocyte precursors. Together, this dual cellular and vesicular signaling helps tighten blood-brain barrier integrity, reduce oxidative stress around demyelinated axons, and encourage endogenous repair pathways.
Individualized protocol
Tailored to your MS phenotype, MRI findings, and clinical goals
No two multiple sclerosis cases share the exact same lesion distribution, inflammatory activity, or functional priorities. Rather than offering a generic infusion, our medical team thoroughly reviews your brain and spinal cord MRI reports, relapse timeline, current disease-modifying therapies, and physical assessments before proposing a plan. Based on this evaluation, our physicians calibrate the precise cell count of Wharton's jelly MSCs, the concentration of MSC-derived exosomes, and the optimal combination of intrathecal, intravenous, and intranasal administration routes. Before you travel to Istanbul, we explain your tailored protocol, expected stay, and realistic therapeutic objectives in full detail.
Our treatment approach & administration routes
Our four-part neurological protocol for multiple sclerosis
When clinically indicated after reviewing your medical records, our medical team combines four complementary biological administration pathways using GMP-certified Wharton's jelly MSCs and exosomes to reach both systemic immune networks and the central nervous system.
01
Intrathecal WJ-MSC Administration
Performed via lumbar puncture with or without sedation depending on clinical circumstances, intrathecal administration delivers fresh, GMP-certified Wharton's jelly-derived MSCs directly into the cerebrospinal fluid (CSF). Because the CSF bathes the spinal cord and cerebral ventricles, this pathway bypasses the blood-brain barrier entirely, allowing the cells to release BDNF, GDNF, HGF, and anti-inflammatory cytokines in close proximity to demyelinated lesions, stressed axons, and activated microglia.
Role in your protocolServes as the primary central nervous system delivery pathway in your protocol when direct CSF bioavailability is indicated after reviewing your brain and spinal MRI scans and coagulation status.
02
Intravenous WJ-MSC Administration
Systemic intravenous infusion introduces Wharton's jelly-derived MSCs into the bloodstream, where they interact with peripheral lymphoid organs and circulating immune cells. Through paracrine signaling, intravenous WJ-MSCs promote regulatory T-cell (Treg) expansion, shift peripheral macrophages from pro-inflammatory M1 to reparative M2 states, and help stabilize the vascular endothelium of the blood-brain barrier.
Role in your protocolForms the systemic immune-modulatory foundation of your protocol, addressing the peripheral-to-central inflammatory cross-talk that drives MS activity and systemic fatigue.
03
Intravenous WJ-MSC Exosome Administration
Wharton's jelly MSC-derived exosomes are purified nanoscale extracellular vesicles (30–150 nm) enriched with neuroprotective proteins, growth factors, and regulatory microRNAs. Because of their microscopic size, intravenously infused exosomes circulate freely without pulmonary capillary trapping and cross the blood-brain barrier to deliver repair instructions directly to oligodendrocyte precursors, neurons, and vascular endothelial cells.
Role in your protocolAdministered alongside or in sequence with WJ-MSCs to amplify intercellular repair signaling and provide immediate vesicular support without adding cellular volume.
04
Intranasal Exosome Administration
Non-invasive intranasal delivery applies concentrated WJ-MSC-derived exosomes to the upper nasal mucosa, engaging the olfactory and trigeminal neural pathways that connect the nasal cavity to the brain. This needle-free route is designed to deliver anti-inflammatory and neurotrophic vesicular cargo toward central neural circuits to complement intrathecal and intravenous administration.
Role in your protocolIncluded as a gentle, non-invasive central adjunct; we note transparently that the exact proportion of intranasally administered exosomes reaching specific human brain regions remains under clinical investigation.
What we aim to achieve
How biological repair signaling connects to your clinical goals
Before your treatment in Istanbul, our medical team establishes clear baseline documentation and follows your progress through structured check-ins at 1, 3, and 6 months alongside your home neurologist.
01
Neuroinflammation control & MRI baseline comparison
By modulating autoreactive T/B-cell signaling and calming central microglial activation, the protocol aims to support a quieter inflammatory environment within the brain and spinal cord. We review your baseline MRI reports and relapse history before treatment so you and your local neurologist can monitor lesion stability on future follow-up scans.
02
Mobility, balance & motor signal conduction
Delivering neurotrophic factors (BDNF, GDNF, NGF) and exosomal microRNAs into the cerebrospinal fluid aims to nourish exposed axons and support oligodendrocyte maintenance along motor pathways. During follow-up, we track practical changes in walking endurance, balance confidence, limb coordination, and hand dexterity.
Chronic neuroinflammation and axonal mitochondrial stress are major drivers of debilitating MS fatigue and neuropathic tingling. As systemic and central cytokine levels are modulated and cellular bioenergetics are supported, we monitor improvements in daytime energy, mental clarity, sensory comfort, and daily quality of life.
04
Procedure tolerability & structured 1, 3, and 6-month follow-up
Every administration in Istanbul is performed under close physician supervision with full GMP laboratory viability documentation. Following your return home, our medical team conducts scheduled reviews at 1, 3, and 6 months to track your functional trajectory alongside your neurologist's ongoing care.
How treatment is personalized
How our medical team evaluates your MS case
When you contact us, we request your medical history, diagnosis, and imaging reports. Uzm. Dr. Cihan Bolat and our medical team evaluate your information, design an individualized protocol where clinically appropriate, and explain the proposed biologics, administration routes, therapeutic objectives, and costs before you arrange travel to Istanbul.
Medical history & reports we request
Neurologist diagnosis summary detailing your MS phenotype, onset, and symptom timeline
Recent brain and spinal cord MRI reports and images
Current list of disease-modifying therapies, medications, and relevant medical history
Recent functional assessments (such as EDSS or mobility notes) if available
Recent routine blood tests (CBC, liver and kidney function, and infectious screening)
Clinical suitability & timing checks
Active systemic infection, fever, or acute febrile illness requiring medical resolution before travel
An acute, unstabilized neurological relapse requiring immediate inpatient corticosteroid or emergency management
Unreviewed anticoagulation or spinal anatomy contraindications prior to an intrathecal procedure
Severe instability in major organ systems that makes international travel or elective procedures unsafe
What the patient journey looks like
From your first inquiry to individualized treatment in Istanbul
Reach out regarding your condition and share your medical history, diagnosis, imaging, and relevant lab reports via our secure form or WhatsApp.
02
Medical team evaluation & protocol design
Our medical team evaluates your records and, where clinically appropriate, develops an individualized Wharton's jelly MSC and exosome protocol.
03
Transparent explanation of protocol & costs
We explain the proposed treatment, specific biologics, administration routes, intended therapeutic objectives, stay timeline, and itemized costs.
04
Arrange treatment in Istanbul & follow-up
Review your individualized proposal, schedule your visit to Istanbul with private airport and clinic transfers, and continue with structured 1, 3, and 6-month follow-up.
2026 cost & protocol planning
Multiple sclerosis treatment cost in Istanbul
Once our medical team evaluates your records and develops your individualized protocol, we provide a clear, itemized proposal explaining the recommended Wharton's jelly MSC and exosome dosages, administration routes, length of stay, and total cost — including GMP laboratory quality certificates, clinical monitoring, and VIP airport and hotel transfers.
Our 2026 neurological program band ranges from $9,000–$25,000 depending on cell dosage, exosome concentration, and whether intrathecal, intravenous, and intranasal routes are combined.
Total Wharton's jelly MSC cell count and MSC-derived exosome dosage tailored to your protocol
Combination of administration routes (intrathecal with or without sedation, intravenous, and intranasal)
Number of treatment sessions, hospital procedure setting, and physician monitoring during your stay
GMP laboratory release documentation, VIP airport/clinic transfers, and 1, 3, and 6-month follow-up
Which combination of intrathecal WJ-MSCs, intravenous WJ-MSCs, intravenous exosomes, and intranasal exosomes is recommended for my MS profile?
02
Whether intrathecal administration will be performed with or without sedation based on my clinical circumstances and comfort.
03
What specific biological and functional objectives the proposed protocol aims to support alongside my current MS medications.
04
My exact itemized treatment cost, how many days I will stay in Istanbul, and how post-treatment follow-up is organized.
Evidence & important considerations
Clinical evidence and important scientific context
Clinical studies in multiple sclerosis evaluate mesenchymal stromal cells and extracellular vesicles for their safety, immunomodulatory effects, and trophic support. Because clinical responses vary between individuals based on disease stage and lesion biology, regenerative cell therapy is offered as a supportive biological intervention rather than a guaranteed cure.
Randomized double-blind crossover trial, 144 people with active MS
Finding
Demonstrated a favorable short-term safety and infusion tolerability profile, while a single intravenous dose alone did not reduce the primary count of gadolinium-enhancing MRI lesions at week 24.
Limitation
Evaluated a single intravenous bone-marrow MSC dose rather than multi-route Wharton's jelly MSC and intrathecal/exosome protocols.
Early-phase clinical study in active multiple sclerosis
Finding
Reported good clinical tolerability with exploratory improvements in disability scores, symptom stability, and inflammatory cytokine profiles during follow-up.
Limitation
Early-phase sample size and follow-up duration mean individual outcomes vary and patients should maintain ongoing neurological supervision.
Frequently asked questions about multiple sclerosis
Depending on your individualized protocol, we combine intrathecal WJ-MSC administration (into the cerebrospinal fluid, with or without sedation depending on clinical circumstances), intravenous WJ-MSC infusion, intravenous WJ-MSC exosomes, and non-invasive intranasal exosomes.
Request Free Medical Evaluation
Begin a personalized treatment conversation with our medical team.
Share your case in confidence. Our international coordinators review every enquiry and respond within 24 hours, in your language.
